Long-term risk of ESRD in IgAN; validation of Japanese prognostic model in a Norwegian cohort.

@article{Bjrneklett2012LongtermRO,
  title={Long-term risk of ESRD in IgAN; validation of Japanese prognostic model in a Norwegian cohort.},
  author={Rune Bj{\o}rneklett and Bj{\o}rn Egil Vikse and Leif Bostad and Torbj{\o}rn Leivestad and Bjarne Magnus Iversen},
  journal={Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association},
  year={2012},
  volume={27 4},
  pages={
          1485-91
        }
}
  • R. Bjørneklett, B. Vikse, +2 authors B. Iversen
  • Published 1 April 2012
  • Medicine
  • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
BACKGROUND Recently, a Japanese model used to predict 10-year risk of end-stage renal disease (ESRD) in IgA nephropathy (IgAN) patients was published. We tested the applicability of the Japanese model in predicting 10- to 20-year risk of ESRD and all-cause mortality in a cohort of Norwegian IgAN patients. METHODS A cohort of IgAN patients (1988-2004) were identified in the Norwegian Kidney Biopsy Registry (NKBR) and ESRD or death during follow-up through 2008 was identified through record… 
Addition of eGFR and Age Improves the Prognostic Absolute Renal Risk-Model in 1,134 Norwegian Patients with IgA Nephropathy
TLDR
The ARR model significantly stratified the IgAN cohort according to risk of ESRD/death and substantially improved its accuracy in a nationwide cohort of IgAN patients.
Evaluating a New International Risk-Prediction Tool in IgA Nephropathy.
TLDR
Two full prediction models were shown to be accurate and validated methods for predicting disease progression and patient risk stratification in IgAN in multi-ethnic cohorts, with additional applications to clinical trial design and biomarker research.
Clinical decision support system for end-stage kidney disease risk estimation in IgA nephropathy patients.
  • F. Pesce, M. Diciolla, +9 authors F. Schena
  • Medicine
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2016
TLDR
This CDSS provides useful additional information for identifying 'high-risk' IgAN patients and may help stratify them in the context of a personalized medicine approach.
Utilizing the MEST score for prognostic staging in IgA nephropathy
TLDR
In the present cohort, adding C lesions to the MEST score did not improve the models prognostic value, and patients can be divided into risk classes based on their MEST scores, which provide valuable prognostic information at the time of diagnosis.
Mortality in IgA Nephropathy: A Nationwide Population-Based Cohort Study.
TLDR
Patients with IgAN have an increased mortality compared with matched controls, with one extra death per 310 person-years and a 6-year reduction in life expectancy and similar increases in risk were seen in comparisons with siblings and spouses.
Mortality in patients with IgA nephropathy.
TLDR
Mortality in patients with IgAN was twice the expected rate, but not significantly increased before RRT, and the risk of end-stage renal disease was substantially higher than risk of death.
Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort
TLDR
A new statistical approach has identified clinical and histological risk factors associated with outcome in children and young adults with IgAN and identified a significantly high probability of proteinuria remission during follow-up and a higher remission rate following treatment with corticosteroid and/or immunosuppressive therapy.
Mortality of IgA Nephropathy Patients: A Single Center Experience over 30 Years
TLDR
It is demonstrated that overall mortality in IgAN patients was higher than that of GP, and strategies optimized to alleviate major renal risk factors are warranted to reduce patient mortality.
External Validation of the International IgA Nephropathy Prediction Tool.
TLDR
Both full models demonstrated remarkable discrimination, acceptable calibration, and satisfactory clinical utility in this study, and the relatively short follow-up time may have limited the validation of these models.
An update on predicting renal progression in IgA nephropathy
TLDR
Proteinuria, estimated glomerular filtration rate (GFR), and blood pressure at the time of biopsy can be used to accurately predict prognosis when combined with MEST, instead of using 2 years of follow up data.
...
1
2
3
...

References

SHOWING 1-10 OF 31 REFERENCES
A scoring system to predict renal outcome in IgA nephropathy: a nationwide 10-year prospective cohort study
TLDR
This validated scoring system to quantitatively estimate ESRD risk during the 10-year follow-up of IgAN patients will serve as a useful prognostic tool in clinical practice.
A scoring system to predict renal outcome in IgA nephropathy: from a nationwide prospective study.
  • K. Wakai, T. Kawamura, +6 authors H. Sakai
  • Medicine
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2006
TLDR
Although the quality of some data collected by the mail survey is limited and the influence of therapy could not be considered, this scoring system will serve as a useful prognostic tool for IgA nephropathy in clinical practice.
IgA nephropathy: prognostic classification of end-stage renal failure. L'Association des Néphrologues de l'Est.
  • L. Frimat, S. Briançon, +4 authors M. Kessler
  • Medicine
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 1997
TLDR
These classifications identify groups at high risk of end-stage renal failure in IgAN and Therapeutic studies should focus on these groups.
Proteinuria patterns and their association with subsequent end-stage renal disease in IgA nephropathy.
TLDR
In a high-risk patient with IgAN, the current 24-h UP and SC measurements are as good predictors of subsequent ESRD as Up and SC trends and levels over the prior year, and females have poorer outcomes than males.
Clinico-pathological correlations and long-term follow-up of 253 United Kingdom patients with IgA nephropathy. A report from the MRC Glomerulonephritis Registry.
TLDR
Patients with impaired renal function and/or those with a reduced serum albumin are significantly more likely to progress to end-stage renal failure within 10 years and marked similarities between the UK experience of IgA nephropathy and the published European experience are indicated.
Toward individual prognosis of IgA nephropathy.
TLDR
The individual prognosis of adult IgA nephropathy patients was studied using the proportional hazards model for the time from biopsy until endstage renal disease and the estimated 5-year survival probability as predicted by the model was compared with the actual outcome.
Prognostic factors in mesangial IgA glomerulonephritis: an extensive study with univariate and multivariate analyses.
Deterioration of GFR in IgA nephropathy as measured by 51Cr-EDTA clearance.
TLDR
It is confirmed that single or repeated determinations of clearance of creatinine are of little value in separating a normal GFR from a slightly decreased one, but more reliable in detecting a markedly reduced GFR.
Remission of proteinuria improves prognosis in IgA nephropathy.
TLDR
It is found that glomerular filtration rate (GFR) declined at -0.38 +/- 0.61 ml/min per 1.73 m2/mo overall, with 30% of subjects reaching end-stage renal disease and Multivariate analysis revealed that proteinuria during follow-up was the most important predictor of the rate of GFR decline.
A tricontinental view of IgA nephropathy.
  • C. Geddes, V. Rauta, +5 authors D. Cattran
  • Medicine
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2003
TLDR
The findings are consistent with the hypothesis that geographical variability in long-term outcome of IgAN is explained by lead-time bias and inclusion of milder cases in centres with apparent good outcome, but do not exclude the possibility that some of the variability is due to other factors such as genetics, diet or treatment.
...
1
2
3
4
...